4 citations
,
July 2024 in “Pharmacology Research & Perspectives” Ritlecitinib is safe and may effectively treat alopecia areata.
April 2025 in “The Journal of Dermatology” Janus kinase inhibitors may help treat cutaneous T-cell lymphoma, but more research is needed.
19 citations
,
September 2013 in “Psychoneuroendocrinology” Blocking CYP17A1 enzyme may help improve certain brain function issues related to dopamine.
18 citations
,
March 1990 in “Archives of Dermatology” Cyclosporine cleared a woman's resistant skin condition quickly and kept it away for over a year.
1 citations
,
March 2021 in “Phytomedicine plus” Cernitin™, a pollen extract, was found to significantly reduce pain and inflammation in rats with chronic prostatitis, suggesting it could be a useful alternative to certain anti-inflammatory drugs.
5 citations
,
January 2018 in “Indian Journal of Dermatology/Indian journal of dermatology” A woman got a skin rash from taking aceclofenac, which went away after she stopped the drug.
1 citations
,
July 2014 in “Our Dermatology Online” The patient with both scarring and non-scarring hair loss showed complex immune reactions and improved with steroid treatment.
4 citations
,
August 2010 in “Acta Biologica Hungarica” New steroidal compounds moderately block an enzyme related to testosterone conversion, less effectively than finasteride.
3 citations
,
December 2022 in “The Neurologist” CARASIL, a rare genetic disorder, was confirmed in an Arabic woman, highlighting its rarity and need for stroke prevention.
May 2011 in “Psychiatric News” Horizant has risks like other seizure drugs, Johnson & Johnson misled about Risperdal, and Quanterix found a possible link between brain oxygen loss and Alzheimer's markers.
1 citations
,
October 2025 in “International Journal of Dermatology” Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.
January 2021 in “Journal of The European Academy of Dermatology and Venereology” Men with hair loss who take a certain type of medication may experience fewer COVID-19 symptoms.
72 citations
,
July 2008 in “Dermatologic Therapy” CCCA is a scarring hair loss condition mainly in African descent women, possibly caused by genetics and hairstyling, treated with gentle hair care and medications.
September 2025 in “International Journal of Molecular Sciences” Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.
75 citations
,
August 2005 in “Expert Opinion on Pharmacotherapy” Acitretin is effective for certain types of psoriasis, safe for long-term use, and often combined with other treatments.
34 citations
,
August 2002 in “British Journal of Dermatology” ALA-PDT is effective and safe for chronic X-ray dermatitis, providing complete or partial remission.
1 citations
,
October 2025 in “Cureus” Ritlecitinib may cause severe musculoskeletal pain in some alopecia universalis patients.
9 citations
,
October 2025 in “MedComm” PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.
April 2021 in “HIV & AIDS Review” Glycyrrhizinic acid spray showed limited effectiveness in treating anogenital warts in HIV patients with low CD4 levels.
59 citations
,
February 2021 in “BMJ” High doses of cyproterone acetate increase the risk of brain tumors in women, but the risk decreases after stopping the medication.
8 citations
,
July 1996 in “Annals of Internal Medicine” Itraconazole may cause low platelet and white blood cell counts.
7 citations
,
May 1983 in “Geburtshilfe und Frauenheilkunde” Intramuscular cyproterone acetate effectively treats hirsutism and improves skin conditions in women with hyperandrogenism.
December 2024 in “Frontiers in Pediatrics” Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.
December 2023 in “Journal of Science Innovations and Nature of Earth” Tribulus terrestris may protect the liver from drug damage.
October 2002 in “Atherosclerosis Supplements” LDL apheresis lowers inflammation and cardiovascular risk by reducing CRP levels long-term.
October 2017 in “The American Journal of Gastroenterology” Early diagnosis and nutritional support are crucial for managing Cronkhite-Canada Syndrome.
2 citations
,
January 2022 in “JAAD Case Reports” The rash resolved after stopping ponatinib.
Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.
July 2025 in “Journal of Investigative Dermatology” DACC-based dressings are more effective than silver-based ones for treating chronic wounds with antimicrobial resistance.
August 2024 in “Postgraduate Medical Journal” A rare skin reaction from cancer treatment was successfully managed with topical treatments and antihistamines.